questionsmedicales.fr
Maladies de l'appareil digestif
Tumeurs de l'appareil digestif
Tumeurs des voies biliaires
Tumeurs des voies biliaires : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs des voies biliaires : Questions médicales les plus fréquentes",
"headline": "Tumeurs des voies biliaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs des voies biliaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-20",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs des voies biliaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs de l'appareil digestif",
"url": "https://questionsmedicales.fr/mesh/D004067",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'appareil digestif",
"code": {
"@type": "MedicalCode",
"code": "D004067",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs des canaux biliaires",
"alternateName": "Bile Duct Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D001650",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs des canaux biliaires",
"code": {
"@type": "MedicalCode",
"code": "D001650",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.250"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs du cholédoque",
"alternateName": "Common Bile Duct Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D003138",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du cholédoque",
"code": {
"@type": "MedicalCode",
"code": "D003138",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.250.250"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Tumeurs de la vésicule biliaire",
"alternateName": "Gallbladder Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D005706",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de la vésicule biliaire",
"code": {
"@type": "MedicalCode",
"code": "D005706",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.401"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs des voies biliaires",
"alternateName": "Biliary Tract Neoplasms",
"code": {
"@type": "MedicalCode",
"code": "D001661",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yasuni Nakanuma",
"url": "https://questionsmedicales.fr/author/Yasuni%20Nakanuma",
"affiliation": {
"@type": "Organization",
"name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Diagnostic Pathology, Fukui Prefecture Saiseikai Hospital, Japan. Electronic address: nakanumayasu@gmail.com."
}
},
{
"@type": "Person",
"name": "Takashi Sugino",
"url": "https://questionsmedicales.fr/author/Takashi%20Sugino",
"affiliation": {
"@type": "Organization",
"name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan."
}
},
{
"@type": "Person",
"name": "Yasunori Sato",
"url": "https://questionsmedicales.fr/author/Yasunori%20Sato",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Pathology, Kanazawa University School of Medicine, Kanazawa, Japan."
}
},
{
"@type": "Person",
"name": "Hans-Olov Adami",
"url": "https://questionsmedicales.fr/author/Hans-Olov%20Adami",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden."
}
},
{
"@type": "Person",
"name": "Gary E Fraser",
"url": "https://questionsmedicales.fr/author/Gary%20E%20Fraser",
"affiliation": {
"@type": "Organization",
"name": "School of Public Health, Loma Linda University, Loma Linda, California."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy.",
"datePublished": "2022-05-18",
"url": "https://questionsmedicales.fr/article/35583018",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3892/or.2022.8332"
}
},
{
"@type": "ScholarlyArticle",
"name": "Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors.",
"datePublished": "2023-10-27",
"url": "https://questionsmedicales.fr/article/37889441",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11060-023-04466-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.",
"datePublished": "2023-07-13",
"url": "https://questionsmedicales.fr/article/37451404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtho.2023.07.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer.",
"datePublished": "2023-04-20",
"url": "https://questionsmedicales.fr/article/37078282",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/SLA.0000000000005884"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials.",
"datePublished": "2022-07-15",
"url": "https://questionsmedicales.fr/article/35881969",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MOG.0000000000000874"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil digestif",
"item": "https://questionsmedicales.fr/mesh/D004066"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil digestif",
"item": "https://questionsmedicales.fr/mesh/D004067"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs des voies biliaires",
"item": "https://questionsmedicales.fr/mesh/D001661"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs des voies biliaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs des voies biliaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs des voies biliaires",
"description": "Comment diagnostique-t-on une tumeur des voies biliaires ?\nQuels tests sanguins sont utiles pour le diagnostic ?\nQuelle est l'importance de l'IRM dans le diagnostic ?\nPeut-on utiliser la cholangiographie pour le diagnostic ?\nQuels symptômes peuvent alerter sur une tumeur ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs des voies biliaires",
"description": "Quels sont les symptômes courants des tumeurs biliaires ?\nLa jaunisse est-elle un symptôme fréquent ?\nPeut-on avoir des démangeaisons avec une tumeur biliaire ?\nLes nausées sont-elles un symptôme associé ?\nComment la douleur abdominale se manifeste-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs des voies biliaires",
"description": "Peut-on prévenir les tumeurs des voies biliaires ?\nQuels facteurs de risque sont évitables ?\nL'alimentation joue-t-elle un rôle ?\nLes infections chroniques augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs des voies biliaires",
"description": "Quels sont les traitements possibles pour ces tumeurs ?\nLa chirurgie est-elle toujours possible ?\nQuand la chimiothérapie est-elle recommandée ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements ciblés disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs des voies biliaires",
"description": "Quelles complications peuvent survenir ?\nL'obstruction biliaire est-elle grave ?\nLes infections sont-elles fréquentes ?\nQuelles sont les conséquences des métastases ?\nPeut-on prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs des voies biliaires",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de tumeurs biliaires ?\nLes maladies hépatiques augmentent-elles le risque ?\nL'exposition à l'arsenic est-elle un risque ?\nLes antécédents familiaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une tumeur des voies biliaires ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par imagerie (échographie, IRM) et biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les marqueurs tumoraux comme l'ACE et les tests de fonction hépatique."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'IRM dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM permet de visualiser les tumeurs et d'évaluer leur extension."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser la cholangiographie pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la cholangiographie permet de visualiser les voies biliaires et détecter des obstructions."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent alerter sur une tumeur ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales, jaunisse, et démangeaisons peuvent indiquer une tumeur."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des tumeurs biliaires ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur abdominale, jaunisse, et perte de poids."
}
},
{
"@type": "Question",
"name": "La jaunisse est-elle un symptôme fréquent ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la jaunisse est fréquente et résulte d'une obstruction des voies biliaires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des démangeaisons avec une tumeur biliaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les démangeaisons peuvent survenir en raison de l'accumulation de bile."
}
},
{
"@type": "Question",
"name": "Les nausées sont-elles un symptôme associé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les nausées peuvent être présentes en raison de l'irritation du système digestif."
}
},
{
"@type": "Question",
"name": "Comment la douleur abdominale se manifeste-t-elle ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur est souvent localisée dans la partie supérieure droite de l'abdomen."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs des voies biliaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais éviter l'hépatite et l'alcool peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont évitables ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'alcoolisme et l'exposition à des produits chimiques sont des facteurs évitables."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine peut réduire le risque de maladies hépatiques, mais pas spécifiquement."
}
},
{
"@type": "Question",
"name": "Les infections chroniques augmentent-elles le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections chroniques comme l'hépatite B et C augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de plusieurs cancers, y compris biliaires."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements possibles pour ces tumeurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours possible ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la chirurgie dépend de la taille et de l'emplacement de la tumeur."
}
},
{
"@type": "Question",
"name": "Quand la chimiothérapie est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est souvent utilisée pour les tumeurs avancées ou inopérables."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie peut soulager les symptômes et est utilisée en complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements ciblés peuvent être utilisés selon le type de tumeur."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'obstruction biliaire, l'infection et la métastase."
}
},
{
"@type": "Question",
"name": "L'obstruction biliaire est-elle grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des douleurs sévères et des infections hépatiques."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections peuvent survenir en raison de l'obstruction des voies biliaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences des métastases ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les métastases peuvent affecter d'autres organes et compliquer le traitement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'hépatite chronique et l'exposition à des toxines."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de tumeurs biliaires ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 50 ans."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques chroniques comme la cirrhose augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à l'arsenic est-elle un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à l'arsenic est associée à un risque accru de cancers biliaires."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque."
}
}
]
}
]
}
The pathological prognostic factors in pancreatic cancer patients who have received neoadjuvant therapy (NAT) are still elusive. The aim of the present study was to investigate the prognostic potentia...
Stereotactic radiosurgery (SRS) is a method of delivering conformal radiation, which allows minimal radiation damage to surrounding healthy tissues. Adjuvant radiation therapy has been shown to improv...
PubMed was systemically reviewed using the search terms "neoadjuvant radiosurgery", "brain metastasis", and "glioma". ' Clinicaltrials.gov ' was also reviewed to include ongoing phase III trials....
This comprehensive review describes the evolving role for neoadjuvant SRS in the treatment for brain metastases, gliomas, and benign etiologies. We also discuss the potential role for high LET radiati...
Early clinical data is very promising for neoadjuvant SRS in the setting of brain metastases. There are three ongoing phase III trials that will be more definitive in evaluating the potential benefits...
The standard of care (SoC) for medically operable patients with early-stage (stages I-IIIB) NSCLC is surgery combined with (neo)adjuvant systemic therapy for patients with stages II to IIIB disease an...
To describe a high-volume experience with biliary drainage before neoadjuvant therapy (NAT) for patients with operable pancreatic cancer (PC) and characterize the association between biliary adverse e...
Patients with PC presenting with biliary obstruction require durable decompression before NAT....
Patients with operable PC and tumor-associated biliary obstruction were examined and grouped by the presence or absence of a BAE during NAT. The incidence, timing, and management of BAEs are described...
Of 426 patients who received pretreatment biliary decompression, 92 (22%) experienced at least 1 BAE during NAT, and 56 (13%) required repeat intervention on their biliary stent. The median duration o...
During extended multimodal NAT for PC, 22% of patients experienced a BAE. Although BAEs were not associated with a significant interruption of treatment, patients who experienced a BAE had worse OS....
Neoadjuvant therapy (NAT) has been enthusiastically embraced for patients with operable pancreatic cancer (PDAC) in hopes of improving survival. However, the rapid integration of clinical trial data h...
The results of ESPAC-5F, NEOLAP-AIO-PAK-0113, SWOG1505, PREOPANC, HyperAcutePancreas, and ALLIANCE A021501 are reviewed in detail. These studies sequentially evaluate the different neoadjuvant treatme...
NAT is associated with improved survival for patients with borderline resectable PDAC but broader efficacy for resectable PDAC and optimal treatment strategy have yet to be defined....
After neoadjuvant therapy, pathologic analysis of rectal cancer resected specimens may show a complete response in the primary tissue cancer with residual tumor in the lymph nodes (ypT0N+)....
The aim of this study was to describe the 5-year overall survival and factors associated with survival of ypT0N+ patients with rectal cancer who had neoadjuvant therapy followed by surgery and to comp...
We conducted a retrospective analysis....
We used the National Cancer Database....
We identified patients with rectal adenocarcinoma who underwent total neoadjuvant therapy or neoadjuvant chemoradiation followed by surgery between 2006 and 2016. Besides ypT0N+, 5 pathologic categori...
The primary outcome measure was 5-year overall survival....
We included 30,751 patients with rectal adenocarcinoma. A total of 342 patients developed ypT0N+, of whom 181 (52.9%) received total neoadjuvant therapy. Among patients who received total neoadjuvant ...
Limitations include the retrospective nature of this study, lack of variables describing the chemotherapy and radiation regimens used, and paucity of data on disease-specific survival or recurrence....
Developing ypT0N+ was associated with a lower 5-year overall survival than ypT0N0 and ypT1-2N0. However, it was associated with a higher 5-year overall survival than ypT3-4N+. See Video Abstract at ht...
ANTECEDENTES:Después del tratamiento neoadyuvante en el cáncer de recto bajo, el análisis patológico de la pieza operatoria resecada, puede mostrar una respuesta patológica completa del tumor primario...
Immunotherapy has revolutionized the standard of care in multiple aspects of oncology. Given successes in the setting of unresectable hepatocellular carcinoma (HCC) and the advantages of neoadjuvant t...
The utilisation of neoadjuvant immunotherapy has demonstrated promising preliminary clinical outcomes for early-stage resectable non-small-cell lung cancer (NSCLC). Nevertheless, it is imperative to d...
Patients with unresectable hilar cholangiocarcinoma (hCCA) may be eligible for curative treatment through liver transplantation (LT). Neoadjuvant protocols often include radiotherapy (RT), however, th...
A survey was administered to radiation oncologists practicing at LT centers identified through the U.S. Organ Procurement and Transplant Network and the International Cholangiocarcinoma Research Netwo...
Twenty-three centers utilizing neoadjuvant therapy for hCCA were identified. Most respondents (96%) use both chemotherapy and RT as part of their protocol. Elective nodal volumes commonly included the...
These results suggest significant variability of neoadjuvant RT use for hCCA before LT. A wide range of doses and fractionation schemes are utilized with cumulative doses ranging from 40 to 110 Gy (EQ...
Over the past decade, neoadjuvant therapy has become the standard of care for patients with borderline resectable and locally advanced pancreatic cancer. The surgical community remains divided regardi...